The WEP
Clinical Trial
Global Delivery Model (WEP-GDM)
Global Reach.
Local Expertise.
One WEP Experience.
One partner. Worldwide delivery.
Local insight where it matters most.
The WEP GDM brings together global scale and regional expertise to support efficient, high-quality clinical trial delivery across diverse markets, sites, and patient populations.
Designed for biotech companies, the Model brings together global oversight and in-country expertise, helping sponsors navigate complex multinational studies with greater agility, consistency, and control.
The Challenges Faced By Sponsors
Every growing biotech faces the same fundamental choice when conducting clinical trials across multiple countries.
Option 1: Working with a Large Global CRO
Option 2: Working with Multiple Regional CROs
- One-size-fits-all processes and reduced flexibility
- High overheads and complex budgets
- Layers of management and bureaucracy
- Slow decisions, approvals and change
- Limited access to senior leadership
- Variable depth of local market and investigator knowledge
- Communication and accountability can become diluted
- Multiple contracts, negotiations and budgets
- Multiple project managers and stakeholder groups
- Different quality systems, KPIs and reporting approaches
- Different IT systems and operating processes
- Varying regulatory experience and delivery standards
- Increased procurement and administrative burden
- The Sponsor becomes responsible for coordinating the overall program
- No single point of accountability and increased delivery risk
Neither model consistently delivers the simplicity, accountability, agility and local expertise growing biotech companies need.
A Better Way:
The WEP Clinical Trial
Global Delivery Model
WEP provides the reach and capabilities expected from a global CRO while retaining the agility, responsiveness and accessibility of a specialist local CROs.
Our experienced in-house teams are supplemented, where appropriate, by carefully selected local specialists who bring additional regional expertise, established investigator and site relationships and deep knowledge of local regulatory requirements.
One WEP experience, wherever the study takes you.

One Global Team. One Consistent Delivery Model.
One Dedicated Project Team
A consistent WEP team leading delivery across countries.
One Consistent Quality Approach
Committed expectations for quality, performance and execution.
Global Reach with Local Expertise
International capability strengthened by in-country knowledge where it matters.
Scalable Multi-Country Delivery
Add countries and capabilities without rebuilding the Sponsor's operating model.
Direct Access to Experienced Leadership
Responsive decision-making and senior-level accessibility.
Reduced Operational Complexity
WEP coordinates the delivery model so the Sponsor does not have to.
Agility and Responsiveness
A model designed around the needs and pace of emerging and mid-sized biotech companies.
Global Reach. Local Expertise.
Global studies demand more than geographic presence. They require local insights from people who understand local regulatory pathways, healthcare systems, investigators, sites and patient populations, as every region presents its own unique challenges.
The WEP Global Delivery Model brings deep regional insight to key international markets, helping sponsors identify the right sites and investigators, navigate local regulatory requirements, respond quickly to country-specific challenges and execute multinational studies with confidence.
Hover over the map sections below to see the data for each region worldwide.
Global Capabilities and Experience
WEP Clinical delivers global reach and deep therapeutic expertise through a streamlined delivery model, combining proven experience and local insight to support high-quality clinical development worldwide.
50
Countries of Operational Reach and Site Access.
3,300+
Clinical Studies, Trials and Projects Across the Experience Base.
800+
Clinical Research Professionals Across Key Delivery Regions.
5,000+
Clinical Sites Within the Available Global Capability.
120,000+
Patients Supported Across the Experience Base.
20+
Therapeutic Areas Across a Broad Range of Indications.
Phase I–IV Experience Supporting Studies from Early Development Through Post-Approval.
WEP Services
Study Conduct
- Country and site feasibility
- Site selection, activation and patient recruitment
- Study start-up
- Clinical trial management
- Monitoring
- Regulatory strategy and submissions
Biometrics, Safety & Quality
- Data management
- Biostatistics
- Medical writing
- Quality assurance and audit readiness
- Pharmacovigilance and safety support
Specialist Solutions
- Real-world evidence and observational research
- Early Access and Compassionate Use programs
- Market access and HEOR support
- Medical device and IVD research
- Decentralized and patient-focused study solutions, where appropriate
- Global packaging, labelling and distribution services
WEP Therapeutic Expertise
Oncology
- 17,415 patients supported
191 Trials
Cancer research is evolving rapidly, requiring precision medicine approaches, biomarker-driven strategies, and innovative trial designs. We bring deep oncology expertise across solid tumors and hematologic malignancies, including:
- Immuno-oncology and checkpoint inhibitors
- Targeted therapies and precision medicine approaches
- Hematologic malignancies (e.g., leukemia, lymphoma, multiple myeloma)
- Solid tumors across multiple indications
- Adoptive cell therapies, including CAR-T and TCR-T therapies
Our oncology trial capabilities include:
- Expertise in early-phase trials (FIH, Phase I/II) and accelerated development pathways
- Biomarker-driven trial designs to optimize patient selection and treatment response
- Access to a global oncology investigator network with leading cancer research centers
- Advanced imaging and radiology solutions for tumor assessment and response monitoring
With our integrated oncology trial solutions, we help our partners bring next-generation cancer therapies to patients faster.
Rare Diseases
- 6,322 patients supported
77 Trials
Conducting clinical trials for rare diseases presents unique challenges, including small patient populations, complex study designs, and regulatory hurdles. At WEP, we have extensive experience overcoming these challenges by leveraging our:
- Global rare disease patient networks to accelerate recruitment and enrollment
- Adaptive trial designs tailored to meet regulatory expectations
- Decentralized trial capabilities to enhance patient participation
- Strong collaborations with patient advocacy groups to ensure patient engagement and retention
- Regulatory expertise in orphan drug designation and expedited approval pathways (e.g., FDA’s Orphan Drug Program, EMA’s PRIME)
Our team is dedicated to advancing treatments for rare diseases, ensuring that patients who need them most have access to innovative therapies.
Neurology / CNS
- 29,241 patients supported
147 Studies supported
CNS clinical trials present challenges such as long disease progression timelines, complex endpoints, and variability in patient response. We bring deep CNS expertise in:
- Neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s, ALS)
- Neurodevelopmental disorders (e.g., Autism Spectrum Disorder, ADHD)
- Psychiatric conditions (e.g., Depression, Schizophrenia, Bipolar Disorder)
- Rare and complex CNS diseases (e.g., Huntington’s Disease, Duchenne Muscular Dystrophy)
Our capabilities include:
- Advanced biomarker strategies to enhance trial efficiency
- Digital and remote monitoring technologies for real-time patient data collection
- Collaborations with leading CNS research institutions and KOLs
- Regulatory expertise in neurodegenerative and psychiatric drug development
With our CNS-focused trial solutions, we help bring novel therapies to patients with high unmet medical needs.
Cardiovascular
- 20,372 patients supported
81 Trials supported
Cardiovascular and metabolic diseases remain leading global health challenges, requiring efficient clinical trial execution and real-world evidence generation. We have extensive experience in:
- Heart failure, coronary artery disease, and arrhythmias
- Hypertension, hyperlipidemia, and atherosclerosis
- Diabetes (Type 1, Type 2) and metabolic syndrome
- Obesity and lipid disorders
- Rare cardiometabolic conditions
Our expertise includes:
- Global patient recruitment strategies to access diverse populations
- Advanced cardiovascular imaging and biomarker analysis for endpoint evaluation
- Integration of digital health technologies, including wearables and remote monitoring
- Regulatory guidance for cardiovascular outcomes trials (CVOTs) and metabolic disease approvals
By combining scientific expertise, innovative trial designs, and global operational excellence, we support the development of transformative treatments for cardiovascular and metabolic diseases.
Immunology
- 8,031 patients supported
63 Trials supported
WEP supports immunology clinical trials across a range of immune-mediated and inflammatory conditions, including:
- Autoimmune diseases
- Inflammatory disorders
- Dermatological conditions
- Respiratory and allergic diseases
- Rare immunological conditions
Our immunology capabilities include:
- Patient recruitment and retention
- Site and investigator selection
- Biomarker-driven studies
- Complex safety monitoring
- Global trial delivery with local expertise
By combining therapeutic expertise with flexible, patient-focused delivery, we help sponsors advance immunology programmes efficiently across global markets.
Respiratory
- 12,420 patients supported
70 Trials supported
Respiratory clinical trials require careful patient identification, precise endpoint measurement, and strong site engagement. WEP supports studies across a range of respiratory conditions, including:
- Asthma
- Chronic obstructive pulmonary disease (COPD)
- Pulmonary fibrosis
- Bronchiectasis
- Rare respiratory diseases
Our capabilities include:
- Global patient recruitment and site selection
- Respiratory endpoint and biomarker support
- Decentralized and patient-focused study approaches
- Regulatory and operational expertise across global markets
We help sponsors deliver respiratory studies efficiently while maintaining a strong focus on patient experience and study quality.
Dermatology
- 11,438 patients supported
54 Trials supported
Dermatology trials require effective patient recruitment, consistent clinical assessments, and an understanding of conditions that can significantly affect quality of life. Our experience includes:
- Psoriasis
- Atopic dermatitis
- Acne
- Hidradenitis suppurativa
- Rare and inflammatory skin diseases
Our capabilities include:
- Patient recruitment and retention strategies
- Site and investigator selection
- Support for clinical and patient-reported endpoints
- Global trial management across diverse patient populations
WEP combines therapeutic expertise with flexible clinical delivery to help sponsors advance innovative dermatology treatments.
Gastroenterology
- 7,599 patients supported
51 Trials supported
Gastroenterology studies often involve complex disease pathways, long-term patient management, and challenging recruitment requirements. WEP supports clinical research across:
- Crohn’s disease
- Ulcerative colitis
- Irritable bowel syndrome
- Liver diseases
- Other gastrointestinal and inflammatory conditions
Our expertise includes:
- Global site and patient recruitment strategies
- Biomarker and endpoint support
- Patient retention and engagement
- Regulatory and operational trial management
We help sponsors navigate complex gastroenterology studies while maintaining consistent execution across countries and sites.
Endocrinology & Metabolic Disease
- 13,277 patients supported
53 Trials supported
Endocrine and metabolic diseases affect large and diverse patient populations and often require long-term clinical evaluation. Our experience includes:
- Type 1 and Type 2 diabetes
- Obesity
- Metabolic syndrome
- Thyroid disorders
- Other endocrine and metabolic conditions
Our capabilities include:
- Large-scale patient recruitment
- Biomarker and metabolic endpoint support
- Digital and remote monitoring solutions
- Global clinical trial management
WEP supports sponsors in delivering efficient studies designed around the needs of patients with chronic endocrine and metabolic conditions.
Haematology
- 2,305 patients supported
25 Trials supported
Haematology trials can involve complex patient populations, specialist sites, intensive monitoring, and rapidly evolving treatment approaches. WEP supports research across:
- Leukaemia
- Lymphoma
- Myeloma
- Anaemia and blood disorders
- Rare haematological conditions
Our capabilities include:
- Specialist site and investigator identification
- Recruitment of targeted patient populations
- Complex safety and clinical monitoring
- Global coordination across specialist centres
We provide the clinical and operational expertise required to support innovative haematology programmes from study start-up through delivery.
Rheumatology
- 6,451 patients supported
35 Trials supported
Rheumatology studies require long-term patient engagement and careful assessment of complex inflammatory and autoimmune diseases. Our experience includes:
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Lupus
- Other autoimmune and inflammatory conditions
Our capabilities include:
- Patient recruitment and retention
- Specialist investigator and site selection
- Clinical endpoint and biomarker support
- Global study management
WEP helps sponsors deliver rheumatology trials with the flexibility and local expertise needed to support patients across multiple markets.
Nephrology
- 5,117 patients supported
24 Trials supported
Nephrology trials often involve medically complex patients and require close monitoring of disease progression, safety, and long-term outcomes. WEP supports studies across:
- Chronic kidney disease
- Acute kidney injury
- Diabetic kidney disease
- Glomerular diseases
- Rare renal conditions
Our capabilities include:
- Specialist site and investigator selection
- Patient recruitment and retention
- Renal endpoint and biomarker support
- Global clinical and regulatory coordination
We help sponsors manage the complexity of nephrology studies while maintaining consistent, high-quality trial delivery.
Ophthalmology
- 4,364 patients supported
24 Trials supported
Ophthalmology trials require specialist investigators, precise clinical assessments, and access to targeted patient populations. Our experience includes:
- Age-related macular degeneration
- Diabetic eye disease
- Glaucoma
- Retinal disorders
- Rare ophthalmic diseases
Our capabilities include:
- Specialist ophthalmology site identification
- Targeted patient recruitment
- Imaging and visual endpoint support
- Global clinical trial coordination
WEP combines therapeutic knowledge with experienced clinical delivery to support the development of new treatments for sight-threatening conditions.
Infectious Diseases and Vaccines
- 8,036 patients supported
55 Studies supported
The rapid emergence of infectious diseases demands agile clinical trial execution, global site networks, and expertise in vaccine development. Our experience spans:
- Bacterial, viral, and fungal infections
- Respiratory infections (e.g., COVID-19, influenza, RSV, pneumonia)
- Tropical and neglected diseases (e.g., malaria, dengue, tuberculosis)
- Antimicrobial resistance (AMR) and novel anti-infectives
- Vaccine development and pandemic preparedness
We support infectious disease and vaccine trials with:
- Global site networks with high-incidence patient populations
- Experience with challenge studies and controlled human infection models (CHIMs)
- Rapid-response trial capabilities for emerging infectious threats
- Expertise in vaccine safety monitoring and immunogenicity assessment
Our end-to-end infectious disease trial solutions help sponsors accelerate the development of lifesaving treatments and vaccines.
Advanced Therapies, including CAR-T and ATMPs
32 Patients per trial
The field of Advanced Therapy Medicinal Products (ATMPs) requires specialized expertise, regulatory navigation, and innovative trial designs. Our dedicated team has experience in:
- Gene therapies targeting rare genetic disorders and complex diseases
- Cell-based therapies, including stem cell treatments and regenerative medicine
- Tissue-engineered products for orthopedic, dermatological, and cardiovascular applications
- Personalized medicine strategies that optimize patient outcomes based on genetic and biomarker data
We provide:
- Regulatory support for ATMP classifications and expedited approval pathways
- Supply chain and GMP compliance for advanced therapy manufacturing
- Specialized site selection for ATMP clinical trials
- Long-term patient follow-up strategies to meet regulatory safety requirements
Our comprehensive ATMP trial capabilities help bring cutting-edge therapies from the lab to the clinic.
Helping Sponsors Conduct Clinical Trials with Confidence
Whether you are entering new countries, seeking access to specific patient populations or scaling a multinational clinical program, the WEP Global Delivery Model gives you flexibility and expertise to move forward with confidence.
Global Reach. Local Expertise. One WEP Experience.
Get in Touch
If you would like to chat with our team about our CRO Services, then please complete the form or contact us at:
We typically respond in under 24 hours.